Non-small cell lung cancer, BRAF-mutated

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search


Section editor
TravisOsterman.jpg
Travis Osterman, DO, MS
Nashville, TN

Twitter: TravisOsterman
LinkedIn

Note: these are biomarker-specific regimens, please see the main NSCLC page for other regimens.

1 regimens on this page
1 variants on this page


Advanced or metastatic disease, BRAF inhibitor-naive

Dabrafenib & Trametinib

back to top

Regimen

FDA-recommended dose
Study Evidence
Planchard et al. 2016 (BRF113928) Phase II
Planchard et al. 2017 Phase II

All enrolled patients had BRAF p.V600E mutations and had progressed on 1 to 3 prior regimens.

Chemotherapy

Continued until progression

References

  1. Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. contains verified protocol link to PMC article PubMed
  2. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. link to original article PubMed